Bigul

MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Notice Of Board Meeting

MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve the Annual Audited Financial Results of the Company (both Standalone and Consolidated) for the Financial Year ended 31st March, 2022. The Board of Directors will also consider recommendation of dividend, if any, for the Financial Year 2021-22. Please note that as per the Insider Trading Code of the Company, the Trading Window for dealing in Company's shares has been closed for the Company's insiders from 1st April, 2022 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on 30th May, 2022.
16-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors

Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Intention to resign as Statutory Auditors
12-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors

Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Intention to resign as Statutory Auditors
12-05-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish details of issue of duplicate share certificate against loss of share certificate as given below on April 27, 2022 received from our Registrar and Transfer Agent, Bigshare Services Private Limited.
28-04-2022

Marksans Pharma acquires Dubai-based Access Healthcare to expand in MENA region

For the year ended December 2021, Access Healthcare had revenues of Rs 25 crore and a profit after tax of Rs 9.4 crore. The company has no debt on its books.
25-04-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Acquisition

Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of Access Healthcare for Medical Products L.L.C
25-04-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Enclosed herewith kindly find a press release dated 25th April, 2022.
25-04-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Format Of The Initial Disclosure To Be Made By An Entity Identified As A Large Corporate

We confirm that we are not a Large Corporate as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021.
14-04-2022
Bigul

MARKSANS PHARMA LTD. - 524404 - Clarification sought from Marksans Pharma Ltd

The Exchange has sought clarification from Marksans Pharma Ltd on April 8, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.
08-04-2022
Next Page
Close

Let's Open Free Demat Account